☆ 4.7 Letter

Letter: potential selection bias in real-world comparison of ustekinumab versus vedolizumab as a second-line treatment for Crohn's disease-authors' reply

ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2022)

Get Full Text
Add to Collection

Journal

ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 55, Issue 8, Pages 1070-1071

Publisher

WILEY
DOI: 10.1111/apt.16896

Keywords

-

Categories

Gastroenterology & Hepatology Pharmacology & Pharmacy

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.